13,131 Shares in Axonics, Inc. (NASDAQ:AXNX) Bought by International Assets Investment Management LLC

International Assets Investment Management LLC bought a new stake in shares of Axonics, Inc. (NASDAQ:AXNX) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 13,131 shares of the company’s stock, valued at approximately $817,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. HighMark Wealth Management LLC grew its position in shares of Axonics by 200.0% during the 3rd quarter. HighMark Wealth Management LLC now owns 525 shares of the company’s stock valued at $29,000 after buying an additional 350 shares during the last quarter. Exchange Traded Concepts LLC acquired a new position in Axonics in the third quarter valued at approximately $37,000. RiverPark Advisors LLC bought a new position in shares of Axonics during the third quarter valued at approximately $58,000. C M Bidwell & Associates Ltd. raised its position in shares of Axonics by 108.2% during the 3rd quarter. C M Bidwell & Associates Ltd. now owns 1,270 shares of the company’s stock worth $71,000 after purchasing an additional 660 shares during the period. Finally, Covestor Ltd lifted its holdings in shares of Axonics by 40.8% in the 3rd quarter. Covestor Ltd now owns 3,143 shares of the company’s stock worth $176,000 after purchasing an additional 911 shares during the last quarter. 99.48% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Axonics

In related news, insider Karen Noblett sold 11,288 shares of Axonics stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $67.74, for a total value of $764,649.12. Following the transaction, the insider now owns 34,428 shares of the company’s stock, valued at approximately $2,332,152.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Axonics news, insider Karen Noblett sold 11,288 shares of the firm’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $67.74, for a total value of $764,649.12. Following the completion of the transaction, the insider now directly owns 34,428 shares in the company, valued at $2,332,152.72. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Raymond W. Cohen sold 35,161 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $67.74, for a total transaction of $2,381,806.14. Following the sale, the chief executive officer now owns 188,835 shares in the company, valued at approximately $12,791,682.90. The disclosure for this sale can be found here. Insiders have sold 65,837 shares of company stock valued at $4,459,798 over the last three months. Company insiders own 1.85% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on AXNX shares. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $71.00 target price on shares of Axonics in a research report on Thursday, February 29th. Needham & Company LLC reiterated a “hold” rating on shares of Axonics in a research report on Wednesday, January 17th. Wells Fargo & Company restated an “equal weight” rating and issued a $71.00 target price (up previously from $68.00) on shares of Axonics in a research report on Wednesday, January 10th. Truist Financial restated a “hold” rating and issued a $71.00 price target (down previously from $73.00) on shares of Axonics in a research note on Friday, January 12th. Finally, SVB Leerink reiterated a “market perform” rating and set a $71.00 price objective on shares of Axonics in a research report on Friday, January 12th. Eight investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Axonics has an average rating of “Hold” and a consensus price target of $70.73.

Axonics Stock Performance

Shares of AXNX stock opened at $66.47 on Wednesday. The business’s fifty day moving average is $68.00 and its 200-day moving average is $62.59. The stock has a market cap of $3.39 billion, a PE ratio of -511.27 and a beta of 0.56. Axonics, Inc. has a 1 year low of $47.59 and a 1 year high of $69.68.

Axonics (NASDAQ:AXNX) last posted its quarterly earnings results on Wednesday, February 28th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.07. Axonics had a negative net margin of 1.66% and a negative return on equity of 1.00%. The firm had revenue of $109.70 million for the quarter, compared to analyst estimates of $107.33 million. During the same quarter in the previous year, the business posted $0.01 earnings per share. The firm’s quarterly revenue was up 27.7% compared to the same quarter last year. Equities research analysts predict that Axonics, Inc. will post 0.32 earnings per share for the current year.

Axonics Company Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.